Investigates usage of high efficacy therapies in multiple sclerosis, indicating no impact from geographic access to infusion centers.
To characterize geographic access to infusion center locations and the impact on the use of infusion high efficacy disease modifying therapies (DMTs) in multiple sclerosis (MS).
No takes yet. Share an insight, caveat, or question.
McGinley et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: